Free Trial

Codexis (CDXS) Competitors

Codexis logo
$2.32 +0.02 (+0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$2.32 0.00 (-0.22%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CDXS vs. MYGN, ZBIO, VSTM, RIGL, XOMA, VNDA, EBS, SGMO, LXRX, and RGLS

Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

Codexis vs.

Myriad Genetics (NASDAQ:MYGN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.

Myriad Genetics has a net margin of -14.09% compared to Codexis' net margin of -96.35%. Myriad Genetics' return on equity of -4.51% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-14.09% -4.51% -3.07%
Codexis -96.35%-71.56%-38.00%

In the previous week, Myriad Genetics had 8 more articles in the media than Codexis. MarketBeat recorded 16 mentions for Myriad Genetics and 8 mentions for Codexis. Codexis' average media sentiment score of 1.08 beat Myriad Genetics' score of 0.50 indicating that Codexis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
5 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral
Codexis
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Myriad Genetics presently has a consensus target price of $20.61, indicating a potential upside of 189.02%. Codexis has a consensus target price of $8.33, indicating a potential upside of 259.20%. Given Codexis' stronger consensus rating and higher probable upside, analysts plainly believe Codexis is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
3 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.19
Codexis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Myriad Genetics received 127 more outperform votes than Codexis when rated by MarketBeat users. However, 61.47% of users gave Codexis an outperform vote while only 52.88% of users gave Myriad Genetics an outperform vote.

CompanyUnderperformOutperform
Myriad GeneticsOutperform Votes
478
52.88%
Underperform Votes
426
47.12%
CodexisOutperform Votes
351
61.47%
Underperform Votes
220
38.53%

Myriad Genetics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by insiders. Comparatively, 2.1% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Codexis has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$837.60M0.78-$263.30M-$1.41-5.06
Codexis$59.35M3.24-$76.24M-$0.90-2.58

Summary

Codexis beats Myriad Genetics on 9 of the 17 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDXS vs. The Competition

MetricCodexisIndustrial organic chemicals IndustryMedical SectorNASDAQ Exchange
Market Cap$192.18M$2.21B$5.53B$7.93B
Dividend YieldN/A3.98%5.11%4.23%
P/E Ratio-2.6716.6822.5118.54
Price / Sales3.2412.28397.62103.30
Price / CashN/A23.6238.1834.62
Price / Book1.871.376.734.25
Net Income-$76.24M-$13.51M$3.22B$248.18M
7 Day Performance0.87%-0.16%1.58%1.25%
1 Month Performance-7.57%-3.11%4.05%3.76%
1 Year Performance-25.40%-28.73%15.75%5.28%

Codexis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDXS
Codexis
3.4843 of 5 stars
$2.32
+0.9%
$8.33
+259.2%
-21.0%$192.18M$59.35M-2.67250News Coverage
Positive News
MYGN
Myriad Genetics
4.1075 of 5 stars
$7.40
-3.1%
$20.61
+178.5%
-62.1%$682.07M$837.60M-5.692,600Upcoming Earnings
High Trading Volume
ZBIO
Zenas Biopharma
N/A$9.75
+9.3%
$40.00
+310.3%
N/A$407.54M$5M-2.75N/A
VSTM
Verastem
3.2107 of 5 stars
$6.21
+8.2%
$13.89
+123.7%
-24.9%$319.75M$10M-1.9550Upcoming Earnings
Analyst Revision
RIGL
Rigel Pharmaceuticals
2.7516 of 5 stars
$16.93
+0.5%
$36.80
+117.4%
+86.3%$302.49M$179.28M120.94160Upcoming Earnings
XOMA
XOMA
4.0329 of 5 stars
$22.09
+4.3%
$59.67
+170.1%
-5.1%$264.04M$10.22M-6.3510Upcoming Earnings
Positive News
VNDA
Vanda Pharmaceuticals
4.152 of 5 stars
$4.29
-0.9%
$16.50
+284.6%
-5.3%$250.18M$198.77M-13.41290Upcoming Earnings
Short Interest ↑
Positive News
EBS
Emergent BioSolutions
3.9976 of 5 stars
$4.55
-1.5%
$14.33
+215.0%
+183.5%$247.23M$1.01B-1.112,420Upcoming Earnings
SGMO
Sangamo Therapeutics
1.5729 of 5 stars
$0.74
+4.3%
$5.17
+602.0%
+50.0%$165.39M$57.80M-0.98480Upcoming Earnings
LXRX
Lexicon Pharmaceuticals
3.5257 of 5 stars
$0.58
+12.8%
$3.67
+537.7%
-52.5%$141.59M$31.08M-0.77140
RGLS
Regulus Therapeutics
1.7841 of 5 stars
$2.01
-2.4%
$12.75
+534.3%
+247.0%$133.15MN/A-1.8830Upcoming Earnings
Analyst Forecast
Options Volume
News Coverage

Related Companies and Tools


This page (NASDAQ:CDXS) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners